CD22

CD22
识别号
别名	CD22；, SIGLEC-2, SIGLEC2, CD22 molecule
外部ID	OMIM：107266 MGI：88322 HomoloGene：31052 GeneCards：CD22
基因位置（小鼠）
染色体	小鼠7号染色体[1]
终止	30,579,767 bp[1]
RNA表达模式
	; ; ; ;
	查阅更多表达数据
基因本体
分子功能	• 血浆蛋白结合; • carbohydrate binding; • IgM binding; • signaling receptor binding; • protein phosphatase binding; • sialic acid binding; • CD4 receptor binding;
细胞组分	• integral component of membrane; • 细胞膜; • 外排体; • 膜; • 细胞质; • 早期内吞体; • cell surface; • neuronal cell body membrane; • recycling endosome;
生物学过程	• 细胞粘附; • regulation of endocytosis; • regulation of B cell proliferation; • B cell activation; • regulation of immune response; • negative regulation of calcium-mediated signaling; • negative regulation of B cell receptor signaling pathway;
	Sources:Amigo / QuickGO
直系同源
	933
	12483
	无数据
	ENSMUSG00000030577
	P20273
	P35329
NM_024916; NM_001185099; NM_001185100; NM_001185101; NM_001278417;
	NM_001771
	NM_001043317; NM_009845
	NP_001172028; NP_001172029; NP_001172030; NP_001265346; NP_001762
	NP_001036782; NP_033975
	维基数据

CD22，名为分化簇-22（英语：），是成熟B细胞表面的一种跨膜受体，属于SIGLEC家族。[4]

功能

CD22表现于成熟B细胞的表面，也表现于少量未成熟B细胞的表面，其主要功能是避免免疫系统过度激活，可降低罹患自体免疫性疾病的风险。[5]

CD22是一种可高度特异性识别糖基化蛋白（如CD45）的跨膜蛋白，可通过N端的一个免疫球蛋白（Ig）结构域与唾液酸结合。因拥有Ig结构域，CD22也属于免疫球蛋白超家族。人类体内，CD22主要功能为抑制B细胞表面受体的活化。另外，小鼠实验的结果发现B细胞运输至派亚氏淋巴丛的过程亦有CD22的参与。[6]

机制

CD22是B细胞受体的一个辅助受体，其与链接在抗原B细胞受体表面的抗原连接后，自己会被磷酸化，进而活化一些磷酸酶以抑制免疫反应[7]。

蛋白质交互作用

CD22经过实验证明会与以下蛋白质产生交互作用：Grb2[8][9]、PTPN6[9][10][11][12][13]、LYN[8][11]、SHC1[8]和INPP5D[8]。

应用

CD22也可能作为抗癌药物的标的，美国国立卫生研究院正在测试一种名为BL22的免疫毒素，BL22是一种抗CD22的单株抗体，与CD22结合后可以进入细胞中，达到杀死细胞的效果，可能有助于治疗某些种类的白血病[14]。另外一种针对CD22的单株抗体药物Epratuzumab也正在测试中，可能有助于治疗白血病与全身性红斑狼疮[15]。

参考文献

GRCm38: Ensembl release 89: ENSMUSG00000030577 - Ensembl, May 2017
. National Center for Biotechnology Information, U.S. National Library of Medicine.
. National Center for Biotechnology Information, U.S. National Library of Medicine.
Crocker PR, et al. . Glycobiology. February 1998, 8 (2): v. PMID 9498912. doi:10.1093/glycob/8.2.0.
Hatta; et al. . Immunogenetics. 1999, 49 (4): 280–286 [2018-08-15]. doi:10.1007/s002510050494. （原始内容存档于2019-09-24）.
Lee M, Kiefel H, LaJevic MD, Macauley MS, Kawashima H, O'Hara E, Pan J, Paulson JC, Butcher EC. . Nature Immunology. October 2014, 15 (10): 982–95. PMC 4222088 . PMID 25173345. doi:10.1038/ni.2983.
Dörner T, Shock A, Smith KG. 31 (5). International Reviews of Immunology. 2012. doi:10.3109/08830185.2012.709890.
Poe JC, Fujimoto M, Jansen PJ, Miller AS, Tedder TF. . The Journal of Biological Chemistry. June 2000, 275 (23): 17420–7. PMID 10748054. doi:10.1074/jbc.M001892200.
Otipoby KL, Draves KE, Clark EA. . The Journal of Biological Chemistry. November 2001, 276 (47): 44315–22. PMID 11551923. doi:10.1074/jbc.M105446200.
Blasioli J, Paust S, Thomas ML. . The Journal of Biological Chemistry. January 1999, 274 (4): 2303–7. PMID 9890995. doi:10.1074/jbc.274.4.2303.
Greer SF, Justement LB. . Journal of Immunology. May 1999, 162 (9): 5278–86. PMID 10228003.
Law CL, Sidorenko SP, Chandran KA, Zhao Z, Shen SH, Fischer EH, Clark EA. . The Journal of Experimental Medicine. February 1996, 183 (2): 547–60. PMC 2192439 . PMID 8627166. doi:10.1084/jem.183.2.547.
Adachi T, Wienands J, Wakabayashi C, Yakura H, Reth M, Tsubata T. . The Journal of Biological Chemistry. July 2001, 276 (28): 26648–55. PMID 11356834. doi:10.1074/jbc.M100997200.
. ClinicalTrials.gov - U.S. National Institutes of Health. [2018-08-14]. （原始内容存档于2007-10-07）.
. DrugBank. Canadian Institutes of Health Research. [2018-08-16]. （原始内容存档于2016-03-04）.

外部链接

医学主题词表（MeSH）：CD22+Antigen

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[refGRCm38Ensembl-1] GRCm38: Ensembl release 89: ENSMUSG00000030577 - Ensembl, May 2017

[2] . National Center for Biotechnology Information, U.S. National Library of Medicine.

[3] . National Center for Biotechnology Information, U.S. National Library of Medicine.

[pmid9498912-4] Crocker PR, et al. . Glycobiology. February 1998, 8 (2): v. PMID 9498912. doi:10.1093/glycob/8.2.0.

[Hatta1999-5] Hatta; et al. . Immunogenetics. 1999, 49 (4): 280–286 [2018-08-15]. doi:10.1007/s002510050494. （原始内容存档于2019-09-24）.

[6] Lee M, Kiefel H, LaJevic MD, Macauley MS, Kawashima H, O'Hara E, Pan J, Paulson JC, Butcher EC. . Nature Immunology. October 2014, 15 (10): 982–95. PMC 4222088 . PMID 25173345. doi:10.1038/ni.2983.

[7] Dörner T, Shock A, Smith KG. 31 (5). International Reviews of Immunology. 2012. doi:10.3109/08830185.2012.709890.

[pmid10748054-8] Poe JC, Fujimoto M, Jansen PJ, Miller AS, Tedder TF. . The Journal of Biological Chemistry. June 2000, 275 (23): 17420–7. PMID 10748054. doi:10.1074/jbc.M001892200.

[pmid11551923-9] Otipoby KL, Draves KE, Clark EA. . The Journal of Biological Chemistry. November 2001, 276 (47): 44315–22. PMID 11551923. doi:10.1074/jbc.M105446200.

[pmid9890995-10] Blasioli J, Paust S, Thomas ML. . The Journal of Biological Chemistry. January 1999, 274 (4): 2303–7. PMID 9890995. doi:10.1074/jbc.274.4.2303.

[pmid10228003-11] Greer SF, Justement LB. . Journal of Immunology. May 1999, 162 (9): 5278–86. PMID 10228003.

[pmid8627166-12] Law CL, Sidorenko SP, Chandran KA, Zhao Z, Shen SH, Fischer EH, Clark EA. . The Journal of Experimental Medicine. February 1996, 183 (2): 547–60. PMC 2192439 . PMID 8627166. doi:10.1084/jem.183.2.547.

[pmid11356834-13] Adachi T, Wienands J, Wakabayashi C, Yakura H, Reth M, Tsubata T. . The Journal of Biological Chemistry. July 2001, 276 (28): 26648–55. PMID 11356834. doi:10.1074/jbc.M100997200.

[titleBL22_Immunotoxin_in_Treating_Patients_Previously_Treated_With_Cladribine_for_Hairy_Cell_Leukemia_-_Full_Text_View_-_ClinicalTrials.gov-14] . ClinicalTrials.gov - U.S. National Institutes of Health. [2018-08-14]. （原始内容存档于2007-10-07）.

[15] . DrugBank. Canadian Institutes of Health Research. [2018-08-16]. （原始内容存档于2016-03-04）.